Meta-analysis of triple versus dual therapy for primary hypertension shows blood pressure reductions

BackgroundCombination therapy is often required for treating hypertension,but the comparative efficacy and safety of triple versus dual antihypertensive regimens remain to be clarified by the latest evidence-based medical data. This meta-analysis aims to compare the efficacy and safety of dual versus triple antihypertensive drug therapy for adult primary hypertension, providing updated evidence to support clinical decision-making.MethodsA systematic search was conducted across four databases—PubMed, Embase, Cochrane, and Web of Science—up to July 2025 to identify randomized controlled trials comparing dual antihypertensive therapy with triple antihypertensive therapy for treating adult primary hypertension. The primary outcome was mean seated blood pressure; secondary outcomes included blood pressure control rates and adverse events. Screening, data extraction, and quality assessment were performed by two independent researchers.The Cochrane Risk of Bias Assessment Tool was used to evaluate study quality; data analysis was conducted using Stata 15.1 software.ResultsA total of 21 studies involving 17,669 patients were ultimately included. Of these, 6,918 patients received triple therapy and 10,751 patients received dual therapy. Triple therapy reduced systolic blood pressure [WMD: −5.98 mmHg, (95% CI: −7.04, −4.92)] and diastolic blood pressure [WMD: −3.34 mmHg, (95% CI: −4.03, −2.65)]. In the ARB subgroup, valsartan-based triple therapy demonstrated significant blood pressure-lowering effects on systolic blood pressure [WMD = −7.41 mmHg, (95% CI: −8.91 to −5.91)] and diastolic blood pressure [WMD = −4.57 mmHg, (95% CI: −5.65 to −3.49)]. An evaluation of 14 adverse reaction symptoms revealed that triple therapy improved patient fatigue [RR: 0.80, (95% CI: 0.67, 0.96)]. Triple therapy increased the rate of blood pressure control [RR: 1.31, (95% CI: 1.23, 1.39)].ConclusionCompared with the dual-drug regimen, the triple-drug antihypertensive regimen may be more effective for short-term blood pressure control, and its overall safety profile is acceptable. However, the subgroup analyses in this study represent exploratory findings only and cannot be directly used to guide clinical drug selection. Given that, although the evidence for the primary efficacy outcome is of moderate certainty, significant heterogeneity remains, the results should be interpreted with caution.